Hormonal
Basal glucose homeostasis is governed by insulin-independent mechanisms primarily regulated by the brain, whereas glucose tolerance is determined by the interaction between insulin secretion and insulin sensitivity.
Understanding that fasting blood sugar (basal state) and how your body handles meals (glucose tolerance) are controlled by different systems can explain why some treatments work for one but not the other. Fasting glucose is largely managed by brain-mediated, insulin-independent processes, while meal response relies on insulin. This suggests that therapies targeting the brain (like certain GLP-1 agonists) may help basal glucose even if they don't fully restore insulin sensitivity.
whereas glucose tolerance appears to be determined largely by interactions between insulin secretion and insulin sensitivity, basal-state glucose homeostasis is predominated by insulin-independent mechanisms governed largely by the brain.
Why this rating
Based on a synthesis of clinical studies (FSIGT, aging, exercise) and animal models (leptin, FGF1), though largely mechanistic/observational rather than interventional trials in humans.
Source
Distinct Roles for Brain and Pancreas in Basal and Postprandial Glucose Homeostasis
Kimberly M. Alonge et al. · Diabetes · 2023
DOI 10.2337/db22-0969
More from this paper
- Aging is associated with impaired glucose tolerance due to reduced insulin sensitivity and failure of insulin secretion to compensate, without changes in basal glucose or insulin-independent glucose disposal.Good
- Central administration of leptin or FGF1 can reverse basal hyperglycemia in diabetic animal models through insulin-independent mechanisms, without improving glucose tolerance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →